REDWOOD CITY, Calif.--(BUSINESS WIRE)--Maxygen, Inc. (Nasdaq:MAXY) today announced that it has filed a Clinical Trial Authorization (CTA) and received the necessary approvals in the United Kingdom to initiate a first-in-human Phase I trial of MAXY-VII in hemophilia patients. MAXY-VII is the company’s next-generation Factor VIIa protein for the treatment of hemophilia. Patient dosing is on schedule to begin in the second half of this year.
